Gapping down
In reaction to disappointing earnings/guidance: MBLX -30.8%, HIIQ -19.4%, DGLY -17.5%, INVE -13.5%, ANY -13.4%, KSS -10.7%, DARA -5.6%, CADC -4.5%, HIMX -4.1%, LXFT -4%, VOXX -3.8%, VSTO -2.1%, CEL -1.7%, CSCO -0.9%, BGMD -0.7%, HSGX -0.6%
Other news: PBYI -17.9% (co announced publication of four abstracts for presentation at ASCO; treatment effect of PB272 (neratinib) was smaller than expected), ANY -13.4% (signed definitive agreements for a private placement of 1,281,250 Common Shares and Warrants to purchase up to 1,281,250 Common Shares for a gross purchase price of ~$4.1 mln), CAMT -11.2% (is offering to sell its ordinary shares in an underwritten public offering), JONE -10.7% ( launches secondary offering of 5 mln Class A common stock by selling stockholders ), GEVO -8.9% (prices its offering of 4.3 mln common stock units at $4/unit- which includes one common stock share and one Series C warrant), CLSN -7.1% (announced results from its Phase Ib trial for GEN-1 in platinum-resistant ovarian cancer will be presented at the ASCO annual meeting; findings demonstrated an overall clinical benefit of 57% for all treatment arms), NVIV -4.5% (announces an update on initial patients implanted with its Neuro-Spinal Scaffold), OHGI -4.2% (following 100%+ move yesterday), FEYE -2.8% (Cisco CEO downplayed rumors that co may acquire FEYE), BIOC -2.1% (filed for $50 mln mixed securities shelf offering), SD -2% (disclosed exchange agreement with an existing holder), Q -1.1% (priced its 11.86 mln share secondary offering of common stock by existing shareholders at $65.00 per share)
Analyst comments: BMY -2.4% (initiated with a Hold at Berenberg), GSK 1.1% (downgraded to Neutral at UBS
)
In reaction to disappointing earnings/guidance: MBLX -30.8%, HIIQ -19.4%, DGLY -17.5%, INVE -13.5%, ANY -13.4%, KSS -10.7%, DARA -5.6%, CADC -4.5%, HIMX -4.1%, LXFT -4%, VOXX -3.8%, VSTO -2.1%, CEL -1.7%, CSCO -0.9%, BGMD -0.7%, HSGX -0.6%
Other news: PBYI -17.9% (co announced publication of four abstracts for presentation at ASCO; treatment effect of PB272 (neratinib) was smaller than expected), ANY -13.4% (signed definitive agreements for a private placement of 1,281,250 Common Shares and Warrants to purchase up to 1,281,250 Common Shares for a gross purchase price of ~$4.1 mln), CAMT -11.2% (is offering to sell its ordinary shares in an underwritten public offering), JONE -10.7% ( launches secondary offering of 5 mln Class A common stock by selling stockholders ), GEVO -8.9% (prices its offering of 4.3 mln common stock units at $4/unit- which includes one common stock share and one Series C warrant), CLSN -7.1% (announced results from its Phase Ib trial for GEN-1 in platinum-resistant ovarian cancer will be presented at the ASCO annual meeting; findings demonstrated an overall clinical benefit of 57% for all treatment arms), NVIV -4.5% (announces an update on initial patients implanted with its Neuro-Spinal Scaffold), OHGI -4.2% (following 100%+ move yesterday), FEYE -2.8% (Cisco CEO downplayed rumors that co may acquire FEYE), BIOC -2.1% (filed for $50 mln mixed securities shelf offering), SD -2% (disclosed exchange agreement with an existing holder), Q -1.1% (priced its 11.86 mln share secondary offering of common stock by existing shareholders at $65.00 per share)
Analyst comments: BMY -2.4% (initiated with a Hold at Berenberg), GSK 1.1% (downgraded to Neutral at UBS
)